Drug target · GSK3B
GSK-3β
Glycogen synthase kinase-3 beta
1 compound in the CNS pipeline acts on GSK-3β.
Compounds targeting GSK-3β
| Compound | Action | Affinity | Lead program | Developer |
|---|---|---|---|---|
| AL001 (lithium–salicylate–L-proline)primarySmall molecule | Inhibitor | — | Phase 1/2Bipolar disorder | Alzamend Neuro, Inc. |